Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade

被引:31
作者
Reddy, Rishindra M. [2 ]
Yeow, Wen-Shuz [2 ]
Chua, Alex [2 ,3 ]
Nguyen, Duc M. [2 ,3 ]
Baras, Aris [2 ,3 ]
Ziauddin, M. Firdos [2 ]
Shamimi-Noori, Susan M. [2 ]
Maxhimer, Justin B. [2 ]
Schrump, David S. [2 ]
Nguyen, Dao M. [1 ,2 ]
机构
[1] Clin Res Ctr, Room 4W-4-3940,10 Ctr Dr, Bethesda, MD 20892 USA
[2] NCI, Sect Thorac Oncol, Surg Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Res Training Award, NIH, Bethesda, MD 20892 USA
关键词
histone deacetylase inhibitor; Apo2L; TRAIL; type II pathway; apoptosis; caspases; mitochondria;
D O I
10.1007/s10495-006-0484-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apo2L/TRAIL is actively investigated as a novel targeted agent to directly induce apoptosis of susceptible cancer cells. Apo2L/TRAIL-refractory cells can be sensitized to the cytotoxic effect of this ligand by cytotoxic chemotherapeutics. The aim of this study was to evaluate the in vitro tumoricidal activity of the Apo2L/TRAIL + Trichostatin A in cultured thoracic cancer cells and to elucidate the molecular basis of the synergistic cytotoxicity of this combination. Concurrent exposure of cultured cancer cells to sublethal concentrations of Apo2L/TRAIL and Trichostatin A resulted in profound enhancement of Apo2L/TRAIL-mediated cytotoxicity in all cell lines regardless of their intrinsic susceptibility to this ligand. This combination was not toxic to primary normal cells. While Apo2L/TRAIL alone or Trichostatin A alone mediated < 20% cell death, 60 to 90% of cancer cells were apoptotic following treatment with TSA + Apo2L/TRAIL combinations. Complete translocation of Bax from the cytosol to the mitochondria compartment was mainly observed in combination-treated cells and this was correlated with robust elevation of caspase 9 proteolytic activity indicative of activation of the mitochondria apoptogenic effect. Profound TSA + Apo2L/TRAIL-mediated cytotoxicity and apoptosis were completely abrogated by either Bcl2 over-expression or by the selective caspase 9 inhibitor, highlighting the essential role of mitochondria-dependent apoptosis signaling cascade in this process. Moreover, increased caspase 8 activity observed in cells treated with the TSA + Apo2L/TRAIL combination was completely suppressed by Bcl-2 over-expression or by the selective caspase 9 inhibitor indicating that the elevated caspase 8 activity in combination-treated cells was secondary to a mitochondria-mediated amplification feedback loop of caspase activation. These finding form the basis for further development of HDAC inhibitors + Apo2L/TRAIL combination as novel targeted therapy for thoracic malignancies.
引用
收藏
页码:55 / 71
页数:17
相关论文
共 68 条
[1]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348
[2]   A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents [J].
Arizono, Y ;
Yoshikawa, H ;
Naganuma, H ;
Hamada, Y ;
Nakajima, Y ;
Tasaka, K .
BRITISH JOURNAL OF CANCER, 2003, 88 (02) :298-306
[3]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[4]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[5]   A unified model for apical caspase activation [J].
Boatright, KM ;
Renatus, M ;
Scott, FL ;
Sperandio, S ;
Shin, H ;
Pedersen, IM ;
Ricci, JE ;
Edris, WA ;
Sutherlin, DP ;
Green, DR ;
Salvesen, GS .
MOLECULAR CELL, 2003, 11 (02) :529-541
[6]   Bcl-2 overexpression enhances tumor-specific T-cell survival [J].
Charo, J ;
Finkelstein, SE ;
Grewal, N ;
Restifo, NP ;
Robbins, PF ;
Rosenberg, SA .
CANCER RESEARCH, 2005, 65 (05) :2001-2008
[7]   Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck [J].
Chen, ZG ;
Zhang, X ;
Li, MF ;
Wang, ZQ ;
Wieand, HS ;
Grandis, JR ;
Shin, DM .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5930-5939
[8]   Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1 [J].
Chopin, V ;
Slomianny, C ;
Hondermarck, H ;
Le Bourhis, X .
EXPERIMENTAL CELL RESEARCH, 2004, 298 (02) :560-573
[9]  
Doi S, 2004, MOL CANCER THER, V3, P1397
[10]   Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRIAL-induced apoptosis [J].
Evdokiou, A ;
Bouralexis, S ;
Atkins, GJ ;
Chai, F ;
Hay, S ;
Clayer, M ;
Findlay, DM .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) :491-504